You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

NEXIUM IV Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Nexium Iv patents expire, and when can generic versions of Nexium Iv launch?

Nexium Iv is a drug marketed by Astrazeneca and is included in one NDA.

The generic ingredient in NEXIUM IV is esomeprazole sodium. There are seventy-four drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the esomeprazole sodium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Nexium Iv

A generic version of NEXIUM IV was approved as esomeprazole sodium by SUN PHARM on March 18th, 2013.

  Try a Trial

Paragraph IV (Patent) Challenges for NEXIUM IV
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
NEXIUM IV For Injection esomeprazole sodium 20 mg/vial and 40 mg/vial 021689 1 2009-11-23

US Patents and Regulatory Information for NEXIUM IV

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca NEXIUM IV esomeprazole sodium INJECTABLE;INTRAVENOUS 021689-001 Mar 31, 2005 DISCN Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Astrazeneca NEXIUM IV esomeprazole sodium INJECTABLE;INTRAVENOUS 021689-002 Mar 31, 2005 AP RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for NEXIUM IV

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca NEXIUM IV esomeprazole sodium INJECTABLE;INTRAVENOUS 021689-001 Mar 31, 2005 ⤷  Try a Trial ⤷  Try a Trial
Astrazeneca NEXIUM IV esomeprazole sodium INJECTABLE;INTRAVENOUS 021689-001 Mar 31, 2005 ⤷  Try a Trial ⤷  Try a Trial
Astrazeneca NEXIUM IV esomeprazole sodium INJECTABLE;INTRAVENOUS 021689-002 Mar 31, 2005 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for NEXIUM IV

See the table below for patents covering NEXIUM IV around the world.

Country Patent Number Title Estimated Expiration
Yugoslavia 49065 ⤷  Try a Trial
European Patent Office 1020461 Sel de magnésium de l'énantiomère (-) d'omeprazole et son utilisation (Magnesium salt of the (-)-enantiomer of omeprazole and its use) ⤷  Try a Trial
Sweden 9301830 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for NEXIUM IV

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0984957 SPC/GB11/013 United Kingdom ⤷  Try a Trial PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105
0124495 SPC/GB01/006 United Kingdom ⤷  Try a Trial PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727
1020461 91870 Luxembourg ⤷  Try a Trial
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.